Melanoma News

CancerConnect melanoma news, tips, and features provide breaking research stories, helpful tips, and inspiring features related to ovarian cancer. The unique daily cancer news service evaluates all aspects of melanoma research and reports on the developments that are most important to cancer patients and healthcare providers, while the tips and features offer insight into all aspects of melanoma treatment and survivorship.

Share

Melanoma News


OMNI-Connect Gets National Recognition as Valuable Social Media Solution in Medicine (August 13, 2014)

Fort Worth TX/Sun Valley ID – OMNI Health Media announces national recognition of its online support communities, TheGIConnection,TheRAConnection, and Cancer Connect, as valuable resources for... Continue Reading

Largest Study to Date of Pembrolizumab in Advanced Melanoma Shows Promising Activity (July 31, 2014)

The investigational anti-PD-1 antibody pembrolizumab is demonstrating promising survival rates among patients with advanced melanoma. Data from an ongoing Phase 1 trial of the drug were presented at the... Continue Reading

Investigational Drug Pembrolizumab Shows Anticancer Activity in Advanced Melanoma (July 30, 2014)

Recent findings reported in The Lancet indicate that the investigational drug pembrolizumab may be effective in patients with advanced melanoma that has progressed after treatment with Yervoy® (ipilimumab).[1]... Continue Reading

Study of Combination Therapy in Cutaneous Melanoma Stopped Early to Allow Crossover (July 25, 2014)

An Independent Data Monitoring Committee recently recommended that a clinical study of the combination treatment Mekinist™ (trametinib) plus Tafinlar™ (dabrafenib) versus Zelboraf® (vemurafenib) for... Continue Reading

Trial Evaluating Nivolumab in Advanced Melanoma Halted Early Because of Superior Results (July 8, 2014)

Bristol-Myers Squibb announced on Tuesday that its clinical trial evaluating cancer immunotherapy nivolumab, which is being developed in advanced melanoma was halted early after it was determined that... Continue Reading

Enzyme Inhibitor Combined with Yervoy Is Well Tolerated and Shows Tumor Response in Metastatic Melanoma Patients (June 4, 2014)

In a phase 1/2 study presented at the 2014 ASCO meeting, researchers determined a dosing level of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor combined with Yervoy® (ipilimumab) that was well tolerated... Continue Reading

May Is National Skin Cancer Detection and Prevention Month (May 1, 2014)

Sun Valley, ID & Fort Worth, TX—OMNI Health Media (OMNI) announces the launch of skin cancer programs for national skin cancer detection and prevention month. As the month of May brings skin cancer... Continue Reading

Viagra Associated with Increased Risk of Melanoma (April 18, 2014)

Men who take by Viagra (sildenafil) are 84 percent more likely to develop melanoma than men who do not, according to the results of a study published in JAMA Internal Medicine. Melanoma is a potentially... Continue Reading

T-VEC Vaccine Promotes Tumor Shrinkage in Advanced Melanoma (March 28, 2014)

The experimental cancer vaccine talimogene laherparepvec (T-VEC) promoted tumor shrinkage and triggered a systemic immune response in patients with advanced melanoma, according to the results of a study... Continue Reading

Nivolumab Produces Durable Responses in Advanced Melanoma (March 14, 2014)

Nivolumab, an investigational, anti–PD-1 drug, produced durable responses in patients with advanced melanoma, according to the results of a study published in the Journal of Clinical Oncology. Of the... Continue Reading

More Melanoma News

Latest Melanoma News By Stage


Screening/Prevention

May Is National Skin Cancer Detection and Prevention Month (May 1, 2014)

Sun Valley, ID & Fort Worth, TX—OMNI Health Media (OMNI) announces the launch of skin cancer programs for national skin cancer detection and prevention month. As the month of May brings skin cancer into focus, it’s time to increase public understanding... Continue Reading

Viagra Associated with Increased Risk of Melanoma (April 18, 2014)

Men who take by Viagra (sildenafil) are 84 percent more likely to develop melanoma than men who do not, according to the results of a study published in JAMA Internal Medicine. Melanoma is a potentially fatal type of skin cancer that begins in the melanocytes,... Continue Reading

Aspirin Reduces Risk of Melanoma in Women (March 20, 2013)

Women who regularly take aspirin have a reduced risk of developing melanoma, according to the results of a study published in Cancer.[1] What’s more—the longer they take the aspirin, the lower the risk. Of the more than one million new diagnoses of... Continue Reading

Lymphoma Patients and Transplant Recipients at Higher Risk of Melanoma (October 11, 2012)

Individuals with lymphoma or those who have undergone organ transplants are far more likely than the average person to develop—and die from—melanoma, according to the results of a review published in Mayo Clinic Proceedings. Melanoma is a potentially... Continue Reading

Number of Cancer Survivors Will Grow to 18 Million by 2022 (June 25, 2012)

There will be nearly 18 million cancer survivors in the United States by 2022, according to a report by the American Cancer Society and the National Cancer Institute: Cancer Treatment & Survivorship Facts & Figures[1] and an accompanying journal... Continue Reading

More Screening and Prevention

Stages I-II

Melanoma More Deadly in Young White Men than Women (August 12, 2013)

Adolescent and young white men with melanoma are more than 50 percent more likely than their female counterparts to die from the disease, according to the results of a study published in JAMA Dermatology.[1] Melanoma is a deadly type of skin cancer that... Continue Reading

Lymphoseek Approved for Detecting Lymph Nodes in Breast Cancer and Melanoma (April 10, 2013)

The U.S. Food and Drug Administration (FDA) has approved Lymphoseek® (technetium Tc 99m tilmanocept) Injection, a radioactive diagnostic imaging agent that helps doctors locate lymph nodes in patients with breast cancer or melanoma who are undergoing... Continue Reading

Adjuvant Radiotherapy for the Management of High-Risk Malignant Melanoma (September 24, 2012)

Adjuvant radiotherapy significantly improved regional lymphatic control for high-risk patients after therapeutic lymphadenectomy for metastatic melanoma, according to the results of a study published in the Lancet Oncology. Of the more than one million... Continue Reading

Women More Likely to Survive Melanoma Than Men (May 16, 2012)

Women are 30 percent more likely to survive melanoma than men, according to the results of a study published in the Journal of Clinical Oncology.[1] Melanoma is a deadly type of skin cancer that arises from melanocytes, which are cells located in the... Continue Reading

Sentinel Node Biopsy Safe and Effective for Melanomas on Head and Neck (August 10, 2011)

Although the head and neck region is complex and delicate, sentinel lymph node biopsy for melanomas of the head or neck appears to be safe and effective. These results were published in Cancer. Skin cancer is the most commonly diagnosed cancer in the... Continue Reading

More Stages I-II

Stage III

Largest Study to Date of Pembrolizumab in Advanced Melanoma Shows Promising Activity (July 31, 2014)

The investigational anti-PD-1 antibody pembrolizumab is demonstrating promising survival rates among patients with advanced melanoma. Data from an ongoing Phase 1 trial of the drug were presented at the 50th Annual Meeting of the American Society of Clinical... Continue Reading

Investigational Drug Pembrolizumab Shows Anticancer Activity in Advanced Melanoma (July 30, 2014)

Recent findings reported in The Lancet indicate that the investigational drug pembrolizumab may be effective in patients with advanced melanoma that has progressed after treatment with Yervoy® (ipilimumab).[1] These findings build on previous research... Continue Reading

Study of Combination Therapy in Cutaneous Melanoma Stopped Early to Allow Crossover (July 25, 2014)

An Independent Data Monitoring Committee recently recommended that a clinical study of the combination treatment Mekinist™ (trametinib) plus Tafinlar™ (dabrafenib) versus Zelboraf® (vemurafenib) for metastatic cutaneous melanoma patients be stopped... Continue Reading

Enzyme Inhibitor Combined with Yervoy Is Well Tolerated and Shows Tumor Response in Metastatic Melanoma Patients (June 4, 2014)

In a phase 1/2 study presented at the 2014 ASCO meeting, researchers determined a dosing level of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor combined with Yervoy® (ipilimumab) that was well tolerated in metastatic melanoma patients and showed promising... Continue Reading

T-VEC Vaccine Promotes Tumor Shrinkage in Advanced Melanoma (March 28, 2014)

The experimental cancer vaccine talimogene laherparepvec (T-VEC) promoted tumor shrinkage and triggered a systemic immune response in patients with advanced melanoma, according to the results of a study presented at the 2014 Society of Surgical Oncology... Continue Reading

More Stage III

Stage IV

Largest Study to Date of Pembrolizumab in Advanced Melanoma Shows Promising Activity (July 31, 2014)

The investigational anti-PD-1 antibody pembrolizumab is demonstrating promising survival rates among patients with advanced melanoma. Data from an ongoing Phase 1 trial of the drug were presented at the 50th Annual Meeting of the American Society of Clinical... Continue Reading

Investigational Drug Pembrolizumab Shows Anticancer Activity in Advanced Melanoma (July 30, 2014)

Recent findings reported in The Lancet indicate that the investigational drug pembrolizumab may be effective in patients with advanced melanoma that has progressed after treatment with Yervoy® (ipilimumab).[1] These findings build on previous research... Continue Reading

Study of Combination Therapy in Cutaneous Melanoma Stopped Early to Allow Crossover (July 25, 2014)

An Independent Data Monitoring Committee recently recommended that a clinical study of the combination treatment Mekinist™ (trametinib) plus Tafinlar™ (dabrafenib) versus Zelboraf® (vemurafenib) for metastatic cutaneous melanoma patients be stopped... Continue Reading

Trial Evaluating Nivolumab in Advanced Melanoma Halted Early Because of Superior Results (July 8, 2014)

Bristol-Myers Squibb announced on Tuesday that its clinical trial evaluating cancer immunotherapy nivolumab, which is being developed in advanced melanoma was halted early after it was determined that the drug was likely to prolong survival. Nivolumab... Continue Reading

Enzyme Inhibitor Combined with Yervoy Is Well Tolerated and Shows Tumor Response in Metastatic Melanoma Patients (June 4, 2014)

In a phase 1/2 study presented at the 2014 ASCO meeting, researchers determined a dosing level of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor combined with Yervoy® (ipilimumab) that was well tolerated in metastatic melanoma patients and showed promising... Continue Reading

More Stage IV

Recurrent

Largest Study to Date of Pembrolizumab in Advanced Melanoma Shows Promising Activity (July 31, 2014)

The investigational anti-PD-1 antibody pembrolizumab is demonstrating promising survival rates among patients with advanced melanoma. Data from an ongoing Phase 1 trial of the drug were presented at the 50th Annual Meeting of the American Society of Clinical... Continue Reading

Investigational Drug Pembrolizumab Shows Anticancer Activity in Advanced Melanoma (July 30, 2014)

Recent findings reported in The Lancet indicate that the investigational drug pembrolizumab may be effective in patients with advanced melanoma that has progressed after treatment with Yervoy® (ipilimumab).[1] These findings build on previous research... Continue Reading

Study of Combination Therapy in Cutaneous Melanoma Stopped Early to Allow Crossover (July 25, 2014)

An Independent Data Monitoring Committee recently recommended that a clinical study of the combination treatment Mekinist™ (trametinib) plus Tafinlar™ (dabrafenib) versus Zelboraf® (vemurafenib) for metastatic cutaneous melanoma patients be stopped... Continue Reading

Trial Evaluating Nivolumab in Advanced Melanoma Halted Early Because of Superior Results (July 8, 2014)

Bristol-Myers Squibb announced on Tuesday that its clinical trial evaluating cancer immunotherapy nivolumab, which is being developed in advanced melanoma was halted early after it was determined that the drug was likely to prolong survival. Nivolumab... Continue Reading

T-VEC Vaccine Promotes Tumor Shrinkage in Advanced Melanoma (March 28, 2014)

The experimental cancer vaccine talimogene laherparepvec (T-VEC) promoted tumor shrinkage and triggered a systemic immune response in patients with advanced melanoma, according to the results of a study presented at the 2014 Society of Surgical Oncology... Continue Reading

More Recurrent

CancerConnect Cancer Commuity & Discussions


Cancer Types

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Just another WordPress weblog
Facebook Twitter RSS